Q-omics provides the consensus-scored MIR548T profile across patient tissues and cancer cell-line models. MIR548T expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR548T is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR548T RNA expression shows 6,938 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KICH, BRCA, and LAML as cancer lineages where MIR548T shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548T — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548T survival associations across molecular data types. MIR548T RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548T RNA expression–survival associations across cancer types. High MIR548T expression shows unfavorable associations in KICH, KIRP, HNSC, PAAD and MESO, but favorable associations in OV. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR548T RNA expression.
This table summarizes MIR548T tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548T. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548T shows higher tumor expression in BRCA, STAD, ESCA and PRAD. The BRCA box plot shows higher MIR548T RNA expression in tumor versus normal tissue (log2 FC = +0.305, t-test p = .004).
This table shows molecular features associated with MIR548T in patient tissues and cancer cell lines. In patient samples, MIR548T shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
